Serena Group

View 3 open jobs Website LinkedIn Careers Page

Focus: Serena Group is a Cambridge-based biotechnology company specializing in wound care and hyperbaric oxygen therapies, with a focus on rare diseases and chronic ulcer management.

Rare Diseases

Profile data last refreshed 18h ago · AI intelligence enriched 2w ago

Open Jobs

3+2 this month

Stable — net +2 jobs in 30d

2 added, 0 removed. Backfill posture.

Should You Work at Serena Group?

AI assessment

Best suited for mission-driven wound care specialists willing to accept early-stage risk for potential specialty pharma upside.

Why Work Here

Focused niche in high-need wound care market with multiple Phase 4 programs (Intact Fish Skin Graft, Activate™ Matrix, Tri-Membrane Wrap™) approaching commercialization
Innovative product portfolio spanning diagnostic devices (Blue Drop, OneStep Foot Scanners) and advanced biologics (amniotic membrane, perinatal tissue allografts)

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Intact Fish Skin Graft

Venous Leg Ulcer (VLU)

Peak

Phase 4 program positioned for commercial launch in specialty wound care.

Activate™ Matrix

Diabetic Foot Ulcer

Help build intelligence for Serena Group

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Cambridge location provides access to biotech ecosystem and potential for academic collaborations

Watch Out For

Only 1 active job posting suggests minimal hiring and limited career mobility or growth opportunity
No disclosed funding, revenue, or employee count creates uncertainty about financial stability and ability to scale
Early-stage commercialization pipeline with primarily Phase 4 programs and no Phase 1-3 development data may indicate narrow therapeutic validation

Generated by Claude from Serena Group's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Phase 4 extracellular matrix product addressing large diabetic foot ulcer market.

Tri-Membrane Wrap™ DFU

Diabetic Foot Ulcer

Peak

Phase 4 membrane-based therapy advancing toward commercialization.

Pipeline & Clinical Trials

Comparative Study of Clinical Endpoint in DMD: Handheld Myometry (HHM) Versus CINRG Quantitative Mea

Duchenne Muscular Dystrophy

N/A

Clinical Trials (1)

NCT01125709Comparative Study of Clinical Endpoint in DMD: Handheld Myometry (HHM) Versus CINRG Quantitative Measurement System (CQMS)

N/A

Dual-layer perinatal tissue allograft

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT06437028Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.

N/A

Standard of Care

Diabetic Foot Ulcer

N/A

Blue Drop Foot Scanner

Diabetic Foot Ulcers (DFU)

N/A

Evaluating the Durability of Closure for Venous Leg Ulcers

Venous Leg

N/A

OneStep Foot Scanner

Diabetic Foot Ulcer (DFU)